1.73  0.14 (8.81%)		08-25 16:00
Open: 1.62 High: 1.81 Volume: 4,426,542		Pre. Close: 1.59 Low: 1.58 Market Cap: 125(M)

Short term
Mid term
Targets	6-month :	2.11	1-year :	2.46
Resists	First :	1.8	Second :	2.11
Pivot price	1.35
Supports	First :	1.38	Second :	1.12
MAs	MA(5) :	1.48	MA(20) :	1.31
	MA(100) :	1.42	MA(250) :	1.44
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	80	D(3) :	81.9
RSI	RSI(14): 82.4
52-week	High :	2.99	Low :	0.87

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BMEA ] has closed Bollinger Bands are 14% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.81 - 1.82	1.82 - 1.83
Low:	1.56 - 1.57	1.57 - 1.58
Close:	1.72 - 1.73	1.73 - 1.74

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

Tue, 25 Aug 2026
Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation - simplywall.st

Mon, 24 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN

Mon, 24 Aug 2026
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes - Investing News Network

Mon, 24 Aug 2026
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment - Investing.com

Thu, 06 Aug 2026
Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside - TradingView

Wed, 05 Aug 2026
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	68 (M)
Held by Insiders	7.1 (%)
Held by Institutions	40 (%)
Shares Short	10,020 (K)
Shares Short P.Month	13,830 (K)

EPS	-0.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.17
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-63.5 %
Return on Equity (ttm)	-164.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.77
Qtrly Earnings Growth	0 %
Operating Cash Flow	-47 (M)
Levered Free Cash Flow	-28 (M)

PE Ratio	-9.62
PEG Ratio	0
Price to Book value	10.17
Price to Sales	0
Price to Cash Flow	-2.66

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.